Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mu Sun

Showing results (211-220 of 338) with videos related to

Pageof 34
Sort By:
BMC Cancer|May 24, 2012
ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapyJong-Mu Sun, Ji-Youn Sung, Se Hoon Park, et al.
International Journal of Radiation Oncology, Biology, Physics|May 31, 2011
Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapyJong-Mu Sun, Myung-Ju Ahn, Min Jae Park, et al.
JAMA Network Open|March 17, 2023
Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020Sang Ah Chi, Hyeyeon Yu, Yoon-La Choi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 15, 2012
Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?Jong-Mu Sun, Myung-Ju Ahn, Jin Seok Ahn, et al.
Oncotarget|September 15, 2017
Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)Hye Ryun Kim, Joung Soon Jang, Jong-Mu Sun, et al.
The Lancet. Oncology|September 19, 2014
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient dataAntonio Rossi, Paolo Chiodini, Jong-Mu Sun, et al.
Oncoimmunology|February 21, 2020
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatmentKyung Hwan Kim, Joon Young Hur, Jinhyun Cho, et al.
Cancer Medicine|June 23, 2018
Surgically resected T1- and T2-stage esophageal squamous cell carcinoma: T and N staging performance of EUS and PET/CTDong Young Jeong, Min Yeong Kim, Kyung Soo Lee, et al.
Future Oncology (London, England)|October 29, 2024
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancerIsamu Okamoto, Shoichi Kuyama, Nicolas Girard, et al.
Immune Network|January 11, 2021
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 AbsKyung Hwan Kim, Joon Young Hur, Jiae Koh, et al.
Pageof 34

Showing results (211-220 of 338) with videos related to

Sort By:
Pageof 34
BMC Cancer|May 24, 2012
ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapyJong-Mu Sun, Ji-Youn Sung, Se Hoon Park, et al.
International Journal of Radiation Oncology, Biology, Physics|May 31, 2011
Expression of excision repair cross-complementation group 1 as predictive marker for nasopharyngeal cancer treated with concurrent chemoradiotherapyJong-Mu Sun, Myung-Ju Ahn, Min Jae Park, et al.
JAMA Network Open|March 17, 2023
Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020Sang Ah Chi, Hyeyeon Yu, Yoon-La Choi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 15, 2012
Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?Jong-Mu Sun, Myung-Ju Ahn, Jin Seok Ahn, et al.
Oncotarget|September 15, 2017
Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)Hye Ryun Kim, Joung Soon Jang, Jong-Mu Sun, et al.
The Lancet. Oncology|September 19, 2014
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient dataAntonio Rossi, Paolo Chiodini, Jong-Mu Sun, et al.
Oncoimmunology|February 21, 2020
Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatmentKyung Hwan Kim, Joon Young Hur, Jinhyun Cho, et al.
Cancer Medicine|June 23, 2018
Surgically resected T1- and T2-stage esophageal squamous cell carcinoma: T and N staging performance of EUS and PET/CTDong Young Jeong, Min Yeong Kim, Kyung Soo Lee, et al.
Future Oncology (London, England)|October 29, 2024
TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancerIsamu Okamoto, Shoichi Kuyama, Nicolas Girard, et al.
Immune Network|January 11, 2021
Immunological Characteristics of Hyperprogressive Disease in Patients with Non-small Cell Lung Cancer Treated with Anti-PD-1/PD-L1 AbsKyung Hwan Kim, Joon Young Hur, Jiae Koh, et al.
Pageof 34